QL1706 plus chemo and radiation for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IV lung cancer (squamous cell or adenocarcinoma) that has spread to other parts of your body.
- Your cancer does not have a specific gene mutation (like EGFR, ALK, or ROS1) that can be treated with targeted therapy.
- You have at least two tumors that can be measured, including one that has spread to a distant organ.
- You are in generally good health (ECOG performance status 0-1) and have adequate bone marrow, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.